Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
for Follicular Lymphoma (FL)
32 locations incl. Fresno
Sponsor: Genmab
Sex: All·Age: 18+
Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024